Reports Q2 revenue $124.1M, consensus $115.5M. “Our record second quarter results reflect a sustained growth acceleration in our business driven by successful global execution of our key strategic plans,” said Thomas Burns, Glaukos (GKOS) chairman and chief executive officer. “We continue to successfully advance our robust pipeline of novel, dropless platform technologies designed to meaningfully advance the standard of care and improve outcomes for patients suffering from chronic eye diseases.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GKOS:
- Notable companies reporting after market close
- Glaukos price target raised to $117 from $114 at BTIG
- Glaukos announces E.U. MDR certification for iStent infinite
- Glaukos Positioned for Growth with Innovative Epioxa Therapy and First-Mover Advantage in Keratoconus Treatment
- Promising Outlook for Glaukos: Strategic Advancements and Market Growth Drive Buy Rating